Effect of TRI-001 in patients with chronic limb threatening ischemia

Overview

Sponsor-declared trial summary

Key facts

Sponsor

Ferring Ventures GmbH

Participant type

Patients

Age range

18-64 years, 65+ years

Gender

Male and Female

Therapeutic area

Diseases [C] - Cardiovascular Diseases [C14]

Trial duration

1 Nov 2025 → ongoing

Decision date (initial)

2025-04-11

Transition trial

No

Low-intervention

No

Rare-disease indication

No

Vulnerable population

No

Trial design

CTIS Part I — objectives, methods, condition coding

Main objective

Scope: Safety

• Evaluate safety and tolerability of intramuscularly (i.m.) injected TRI 001
• Evaluate therapeutic effect of i.m. injected TRI 001 on target wound size

Secondary objectives 1

1. Evaluate efficacy and safety of i.m. injected TRI 001 on other endpoints relevant for CLTI due to PAD (Rutherford 5)

Conditions and MedDRA coding

Patients with Chronic Limb Threatening Ischemia (CLTI) due to Peripheral Arterial Disease (PAD)

Regulatory references

Scientific advice from competent authorities

European Medicines Agency, Paul-Ehrlich-Institut

Plan to share IPD

No

Eligibility criteria

Principal inclusion / exclusion criteria as submitted by sponsor

Inclusion criteria 6

1. Male or female adult patient, not older than 85 years of age, who have signed an informed consent form either directly or through a legally authorised representative.
2. Objective evidence of CLTI due to PAD (Rutherford 5): a. Minor tissue loss, i.e., ischemic lesions must not have tendon or bone exposure (unless secondary to a minor amputation) b. Persistent, non-healing ischemic wound(s) which are: i. present during at least 2 weeks prior to screening, and ii. at least 1 wound with its surface area ≥3 cm2. iii. likely irreversible wounds (e.g., non healing for >52 weeks) may be excluded at the discretion of the Investigator. excluded at the discretion of the Investigator. c. The index leg is meeting haemodynamic and metabolic criteria assessed in two consecutive examinations performed at least one week apart prior to randomisation (see Section 8.1.8): i. Resting ankle systolic pressure (ASP) <60 millimetre of mercury (mm Hg) in either the dorsalis pedis or posterior tibial arteries; or ii. Resting toe systolic pressure (TSP) <40 mm Hg; or iii. Transcutaneous oxygen pressure (TcPO2) <30 mm Hg. d. Sufficient inflow of aorta, iliac, common femoral artery and profunda assessed by doppler ultrasonography at screening. Definition sufficient inflow is in accordance with the IWGFD PAD Guidelines (Fitridge 2023). e. The patient has no promising conventional approach or is ineligible for revascularisation (including medical, endovascular, or surgical), as confirmed by the iAC (see Section 4.2). The following no-option conditions are considered eligible: i. Type I: patients with no sufficient perfused pedal vessels or with desert foot anatomy ii. Type II: patients with potential pedal target vessel but without suitable autologous or allogenic conduit bypass and no option for endovascular revascularisation iii. Type IV: patients with excessive or prohibitive risk for the revascularisation due to: • comorbidities (e.g., hypertension, coronary artery disease, renal failure, and pulmonary dysfunction) • having undergone failed endovascular surgeries (minimally 2 attempts) or failed open surgeries (minimally 1 attempt). These patients are considered eligible if the iAC deems these patients unsuitable for revascularisation attempts.
3. Patients with adequate organ function defined as following: a. Renal function: estimated glomerular filtration rate (eGFR) of 40 mL/min/1.73 m2 according to the Modification of Diet in Renal Disease (MDRD) equation (See Section 8.2.2) b. Hepatic function: i. Total bilirubin (TB) ≤1.5× upper limit of normal (ULN), and ii. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤3× ULN c. Bone marrow: i. Absolute neutrophil count ≥1.5× 109 cells/L ii. Haemoglobin ≥8.0 g/dL iii. Platelets ≥75× 109 cells/L
4. Currently taking an anti platelet agent (e.g., clopidogrel, ticlopidine, and aspirin etc.) for 2 weeks or more prior to randomisation as part of their standard of care, unless contraindicated or anti-coagulated
5. Patients of reproductive potential must agree to use an accepted and effective form of birth control methods during the study period. Contraceptive methods used by men or women should be consistent with Section 6.2.3 and local regulations.
6. Willing and able to complete all study assessments, follow study instructions and attend all study visits as required, in the opinion of the Investigator

Exclusion criteria 17

1. Presence of any significant disease/disorder (including lab/physical examination/ electrocardiogram (ECG)/medication abnormalities) which is unstable or uncontrolled despite treatment (e.g., aorto-iliac occlusion), or which in the opinion of the Investigator (and if deemed necessary with consultation of the medical monitor), may either put the subject at risk because of participation in the study, may influence the results of the study, or the subject’s ability to participate in the study
2. No-option patients categorised as and confirmed by the iAC (see Section 4.2): a. Type III: Patients with tissue loss that expose vital structures (e.g., bones, tendons) precluding limb salvage of a functional foot. b. Type IV: Patients with a non-functional limb due to paralysis or chronic non-ambulatory status.
3. Evidence of active infection in the target wounds, classified as Wound, Ischemia, foot infection (WIfI) Infection Grade 3 and infected wounds requiring intravenous antibiotics. Diagnosis of osteolysis and osteomyelitis in foot Xray.
4. CLTI with an amputation proximal to a transmetatarsal level (Rutherford 6) in either leg
5. Stroke or acute myocardial infarction/unstable angina within 3 months before screening
6. Severe congestive heart failure symptoms according to New York Heart Association (NYHA) Stage IV
7. Uncontrolled diabetes mellitus (DM) type I or II with haemoglobin A1c (HbA1c) ≥10%
8. Planned major amputation within 4 weeks after randomisation
9. Active malignancy or history of a primary malignancy that has been diagnosed or required therapy within 2 years prior to the planned dose of study drug (exempt are: completely resected basal cell and squamous cell skin cancer, curatively treated localised prostate cancer, and completely resected carcinoma in situ of any site).
10. Patients diagnosed with vasculitis.
11. Evidence of active systemic infection, including active infection with human immunodeficiency virus, hepatitis B or hepatitis C, as determined by hepatitis B surface antigen screening, detection of hepatitis C antibodies, or positive result of hepatitis C polymerase chain reaction analysis
12. Pulmonary disease requiring supplemental oxygen treatment on a daily basis
13. Patients with a severe comorbid disorder who are not expected to survive for more than 6 months in the opinion of the Investigator
14. Patients with ulcers from venous or neuropathic origin on the index leg
15. Patients currently receiving immunosuppressive, chemo or radiation therapy
16. Use of any investigational drug/device within 30 days or 5 half-lives of the investigational drug/device prior to Day 1, whichever is longer, or plans to participate in another study of a drug or device during the study period
17. Is a pregnant or breastfeeding female

Endpoints

Primary and secondary outcome measures (English text)

Primary endpoints 1

1. • The safety profile by assessing the occurrence of Adverse Events (AEs) and clinically significant changes in safety assessments (including vital signs, 12-lead electrocardiogram [ECG], safety laboratory testing [biochemistry, haematology, urinalysis], and other disease related safety measures) • Percentage change from baseline of the target wound size at Month 12

Secondary endpoints 3

1. Key Secondary Endpoints: • Time to complete wound healing of the target wound* on the index leg • Change in rest pain score (Numeric Pain Rating Scale [NPRS], score 0-10) at Month 12 • Change in Vascular Quality of Life (VascuQoL)-6 score at Month 12 • Amputation Free Survival (AFS) of the index leg • Occurrence of Major Adverse Limb Event (MALE) of a vascular cause of the index leg • Occurrence of Major Adverse Cardiac Event (MACE)
2. Important Secondary Endpoints: • Change in number of eligible wounds* present on the index leg at Month 12 • Change in haemodynamic and metabolic measurements of the index leg at Month 12 whenever it’s applicable: o Toe Brachial Index (TBI) o Ankle Brachial Index (ABI) o Transcutaneous oxygen pressure (TcPO2) • All-cause mortality
3. Other Secondary Endpoints: • Occurrence of minor amputations of the index leg

Investigational products

Investigational medicinal products (IMPs), comparators, placebo, auxiliary

Test 1

Placebo 1

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Ferring Ventures GmbH

Sponsor organisation

Ferring Ventures GmbH

Address

Grosse Bleichen 12/14, Neustadt Neustadt

City

Hamburg

Postcode

20354

Country

Germany

Scientific contact point

Organisation

Ferring Ventures GmbH

Contact name

Gilbert Wagener

Public contact point

Organisation

Ferring Ventures GmbH

Contact name

Sibille Engels

Locations

1 EU/EEA country · 6 investigational sites

By country

Investigational sites

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Results and documents

Annex IV summary of results, Annex V layperson summary, and all documents registered in CTIS for this trial

Documents 18 files

Public protocol annexes, IB summaries, regulatory submissions and post-authorisation documents registered in CTIS.

Application history

5 submissions — initial application plus substantial / non-substantial modifications